Medication info
Linarom 2.5/850 mg (Linagliptin, Metformin Hydrochloride)

Linarom 2.5/850 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902778 · Approved 2019.04.30 · Insurance code 645306130

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, provided the following dose adjustment is made. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes when Linagliptin and Metformin are administered together. Taking it along with dietary and exercise therapy can effectively manage blood glucose levels. This contributes to the prevention of complications of diabetes. It is important for patients to continue taking the medication as directed by healthcare professionals while maintaining a healthy lifestyle. This medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients with inadequate glycemic control on metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their existing doses of linagliptin and metformin. 4. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients with inadequate glycemic control on combination therapy with insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, provided the following dose adjustment is made. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Precautions

This medication helps to control blood sugar levels. When taking this medication, be cautious of a rare side effect called lactic acidosis. Lactic acidosis is a serious condition that occurs when lactic acid accumulates excessively in the body, especially at higher risk in patients with poor kidney function or heart disease. This medication should not be administered to certain patients. For example, it should not be taken by those who have an allergy to this medication, patients with type 1 diabetes, patients with severe renal impairment, those with acute myocardial infarction, and pregnant or nursing women. When used with other diabetes medications that pose a risk of hypoglycemia, caution is needed to avoid excessively low blood sugar levels. Particularly, when used in combination with sulfonylureas or insulin, there is a possibility of hypoglycemia, so it is necessary to discuss dosage adjustments with a physician. Since kidney function is crucial, individuals should regularly check their kidney function before starting treatment and during treatment. If kidney function declines, usage of this medication should be halted or adjusted. During acute infections, dehydration, severe trauma, before and after surgery, and before and after radiographic contrast tests, this medication should be temporarily stopped and can be resumed once the condition stabilizes. This medication should be used with caution in patients with liver dysfunction, and it is advisable to avoid use in cases of severe gastrointestinal disorders. Rare side effects such as acute pancreatitis, severe arthralgia, and blistering dermatitis may occur; if such symptoms occur, contact healthcare professionals immediately. This medication can lower vitamin B12 levels, so regular monitoring of vitamin B12 status is necessary if taken for an extended period. Additionally, this medication may interact with multiple drugs, so if taking other medications, be sure to inform your physician or pharmacist. Pregnant women or those planning to become pregnant should avoid taking this medication, and it is not recommended for nursing mothers either. It is not recommended for children under 10 years old or adolescents aged 10-17 years as safety and efficacy have not been sufficiently confirmed. Elderly patients may have reduced kidney function, so it is essential to adjust the dosage and frequently monitor kidney function. In the case of an overdose, there is a risk of lactic acidosis, and immediate medical attention should be sought; if necessary, blood dialysis can be performed to remove the medication. Store this medication out of the reach of children, avoiding moisture, and retaining it in the original container.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 100 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • oral ulcers
  • hepatitis
  • liver dysfunction
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disturbance
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus damage
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • anemia
  • pruritus
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so the bottle must be securely closed and stored in a sealed condition. Avoid storage in extremely hot or cold places, and it is best to keep it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.